Annual results and Q4 2023
Wednesday, January 31, 2024

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)


Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)

Download 2023 epidemiology data (PDF 1.1 MB)
 

Key figures1

Continuing operations2

 Q4 2023
(USD m)
Q4 2022
(USD m)
% change
(USD/cc)
Net sales11,42310,5768 (cc: 10)
Operating income2,5821,75547 (cc: 68)
Net income2,6381,315101 (cc: 130)
EPS (USD)1.290.62108 (cc: 140)
Free cash flow2,1413,462-38

Core
   
Operating income3,8213,6455 (cc: 13)
Net income3,1262,9636 (cc: 11)
EPS (USD)1.531.3910 (cc: 16)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

Q3 2023 results - Tuesday, October 24, 2023

Media release:

English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.6 MB)


Watch the webcast

Download the podcast (MP3 33 MB)

Download the presentation (PDF 3.5 MB)

Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)
 

Key figures1

Continuing operations2

 Q3 2023
(USD m)
Q3 2022
(USD m)
% change
(USD/cc)
Net sales11,78210,49212 (cc: 12)
Operating income1,7621,826-4 (cc: 13)
Net income1,5131,33014 (cc: 37)
EPS (USD)0.730.6120 (cc: 45)
Free cash flow5,0434,05424

Core
   
Operating income4,4053,77217 (cc: 21)
Net income3,5853,03518 (cc: 23)
EPS (USD)1.741.4024 (cc: 29)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities and Discontinued operations include operational results from the Sandoz business.

 

Q2 2023 results - Tuesday, July 18, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)


Watch the webcast

Download the interactive presentation (PDF 2.9 MB)

Download the podcast (MP3 34 MB)

Read the transcript

Novartis Q2 2023 Impact and Sustainability Update (PDF 0.3 MB)
 

Key figures1Q2 2023
(USD m)
Q2 2022
(USD m)
% change
(USD/cc)
Net sales13,62212,7817 (cc: 9)
Operating income2,9202,22831 (cc: 50)
Net income2,3171,69537 (cc: 54)
EPS (USD)1.110.7744 (cc: 62)
Free cash flow23,2753,498-6

Core
   
Operating income4,6684,2709 (cc: 17)
Net income3,8113,43111 (cc: 19)
EPS (USD)1.831.5617 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. Effective January 1, 2023, Novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 48 of the Condensed Interim Financial Report.

Q1 2023 results - Tuesday, April 25, 2023

Media release:

English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.3 MB)


Watch the webcast

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)
 

Key figures1Q1 2023
(USD m)
Q1 2022
(USD m)
% change
(USD/cc)
Net sales12,95312,5313 (cc: 8)
Operating income2,8562,8520 (cc: 9)
Net income2,2942,2193 (cc: 14)
EPS (USD)1.091.009 (cc: 20)
Free cash flow22,7201,39295

Core
   
Operating income4,4134,0838 (cc: 15)
Net income3,6143,25111 (cc: 18)
EPS (USD)1.711.4617 (cc: 25)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. Effective January 1, 2023, Novartis revised its definition of free cash flow, to define free cash flow as net cash flows from operating activities less purchases of property, plant and equipment. To aid in comparability, the prior year free cash flow amounts have been revised to conform with the new free cash flow definition. See page 35 of the Condensed Interim Financial Report.

 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.